Bevacizumab use for recurrent high-grade glioma at McGill University Hospital.

摘要: Background: Bevacizumab, a humanized recombinant anti-vascular endothelial growth factor antibody, was approved in Canada 2010 for the treatment of high-grade glioma. We report effectiveness and safety bevacizumab patients with recurrent gliomas at single institution. Methods: Twenty-seven consecutive glioma (anaplastic glioblastoma) first or subsequent relapse were treated alone combination chemotherapy. The primary endpoint progression-free survival (PFS) secondary endpoints objective response rate, six month PFS, overall (OS), profile. Results: clinical benefit rate (complete partial responses plus stable disease) 59%. Median PFS 4.3 (95% CI, 3.0-10.9) months, 43%. OS after current 8.9 5.8-not reached) months. Ten episodes grade 3/4 adverse events observed nine patients, including fatigue (n = 3), thrombocytopenia 4), myelotoxicity, febrile neutropenia, pulmonary embolism (each n 1). Conclusions: consider efficacy profile is comparable to other cohorts international institutions.